Actavis Takes to the Ice as Official Sponsor of the IIHF Ice Hockey World Championship

PARSIPPANY, New Jersey and ZUG, Switzerland, April 29, 2013 /PRNewswire/ -- Actavis Inc. (NYSE:ACT), a leading specialty pharmaceutical company, today announced that it has entered into a multi-year partnership with ISA International Sports Agency to be the official sponsor of the IIHF Ice Hockey World Championships in Sweden and Finland in 2013 and in Belarus in 2014.

Actavis will be represented both on and alongside the ice during all 64 matches of the world championship, raising awareness of its newly introduced brand identity, which re-establishes the company as a global, integrated specialty pharmaceutical leader focused on developing, manufacturing and distributing generic, brand and biosimilar products in more than 60 countries around the world.

Actavis became the new name for the global pharmaceutical company Watson Pharmaceuticals, Inc., in January 2013, following the company's acquisition of the global generics company the Actavis Group.

"The continuing rise in viewing figures and transmission time have convinced us that the IIHF Ice Hockey World Championships provides an excellent platform for presenting our new brand identity to viewers around the world," said Lars Ramneborn, Actavis' Senior Vice President Europe.

The 2013 IIHF Ice Hockey World Championship will take place in Stockholm, Sweden and Helsinki, Finland, from May 3 – May 19, 2013.

About Actavis, Inc.

Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland.

Actavis is the world's third-largest generics prescription drug manufacturer. Operating as Actavis Pharma, the Company develops, manufactures and markets generic, branded generic, legacy brands and Over-the-Counter (OTC) products in more than 60 countries. The Company is ranked in the top 3 in 12 global markets, the top 5 in 16 global markets, and in the top 10 in 33 global markets. Actavis Pharma also develops and out-licenses generic pharmaceutical products outside the U.S. through its Medis third-party business, the world's largest generic pharmaceutical out-licensing business. Medis has more than 300 customers globally, and offers a broad portfolio of more than 200 products.

Actavis Specialty Brands is the Company's global branded specialty pharmaceutical business, which develops and markets a portfolio of approximately 40 products principally in the United States and Canada that are focused in the Urology and Women's Health therapeutic categories. Actavis Specialty Brands is committed to developing and marketing biosimilars products in Women's Health, Oncology and other therapeutic categories, and currently has a portfolio of 5 biosimilar products in development.

Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, with a capacity of approximately 44 billion units annually. Actavis Global Operations also includes Anda, Inc., the fourth-largest U.S. generic pharmaceutical product distributor in the United States.

For press release and other company information, visit Actavis' Web site at http://www.actavis.com.